Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. magnobeads

MagnoBeads

Removing endotoxins during sepsis: a blood purification platform using magnetic nanoparticles

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 MagnoBeads project word cloud

Explore the words cloud of the MagnoBeads project. It provides you a very rough idea of what is the project "MagnoBeads" about.

dialysis    eth    billion    smei    financially    move    academic    operate    composition    zurich    intensive    million    uniquely    authorization    models    opportunity    sepsis    treat    commercialize    combined    nanoparticles    financial    upscaling    swiss    uuml    stabilizing    treatments    nanoparticle    molecules    regulatory    removing    sized    strategy    huge    purification    strategies    solid    ip    wyss    curative    capitalize    halted    usability    septic    people    symptoms    put    animal    excellent    spin    relieving    gebert    entails    small    responsible    care    30    engineering    endotoxins    receive    patient    treatment    2017    rate    units    selectively    filter    human    founded    employs    hemotune    death    device    evaluation    tested    foundation    cure    19    platform    filtered    off    designed    prototype    position    successfully    z    removes    magnetic    company    blood    proprietary    feasibility    commercialization    market    ongoing    delivering    subsequently    clinical    exists    ready    freedom    mortality    trials    commercial    2026    capture   

Project "MagnoBeads" data sheet

The following table provides information about the project.

Coordinator		 HEMOTUNE AG 

Organization address
address: C/O ETH ZURICH WEINBERGSTRASSE 35 WEH F14
city: ZURICH
postcode: 8092
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Project website http://www.hemotune.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEMOTUNE AG CH (ZURICH) coordinator 50˙000.00

Map

 Project objective

Hemotune is a Swiss academic spin-off company founded in 2017 to commercialize proprietary blood purification technology using uniquely designed magnetic nanoparticles, developed at ETH Zürich. Hemotune is financially supported by Wyss Zurich and the Gebert Rüf foundation to develop a product to treat sepsis. Sepsis affects 19 million people each year, and with a mortality rate of 30% it is the most common cause of death in intensive care units. Currently, no cure for sepsis exists, and treatment focuses on relieving symptoms. Therefore, a huge market opportunity exists for curative sepsis treatments, which is estimated to reach €4.3 billion by 2026.

Using its proprietary blood purification technology, hemotune aims to capitalize on this market opportunity by developing a dialysis-like device that removes endotoxins (molecules responsible for sepsis) from the blood. This device employs magnetic nanoparticles to selectively capture endotoxins, which are subsequently filtered out of the blood by a magnetic filter. By removing these endotoxins, the septic response is halted, stabilizing the patient. This technology was successfully tested in small-scale animal models, and now R&D activities will focus on developing a human-sized prototype product, ready for clinical evaluation.

Financial support from the SMEi phase 1 will be used to assess the technical and commercial feasibility of the nanoparticle-based blood purification platform as a treatment strategy for sepsis. Technical feasibility includes usability engineering, and feasibility studies into the upscaling, and into regulatory feasibility to receive market authorization. Commercial feasibility entails a freedom to operate analysis, and composition of solid IP and commercialization strategies. This SMEi phase 1 feasibility study, combined with the ongoing R&D delivering the prototype product, put hemotune in an excellent position to rapidly move forward towards clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGNOBEADS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGNOBEADS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

COUNTMITMENT (2019)

NATURAL CAPITAL ACCOUNTANCY TO IMPROVE REPORTING AND ENVIRONMENTAL PERFORMANCE

Read More